Nasal cavity microbiota features among people who have had COVID-19
https://doi.org/10.17021/1992-6499-2023-4-97-102
Abstract
The new coronavirus infection of 2019 is accompanied by damage to a number of organs, tissues, systems of the human body, including the microbiome. However, some aspects of the influence of this infection on the state of the microbiota of individual biotopes in individuals vaccinated with the Gam-COVIDVac vaccine require further research.
Purpose: to study the characteristics of the nasal microbiota in vaccinated Gam-COVID-Vac and non-vaccinated individuals who have had COVID-19.
Materials and methods: 60 people aged 18 to 23 years old were examined, divided into 3 equal groups: group 1 – vaccinated, sick after vaccination, group 2 – not vaccinated, recovered, group 3 (control) – not sick and not vaccinated. In all examined persons, muconasal secretions from the nasal cavity were examined using conventional bacteriological methods.
Results. In the group of unvaccinated and recovered patients, the coronavirus infection caused a significant change in the composition of the nasal cavity microbiota in the form of a significant increase in the number of opportunistic microorganisms (S. aureus, E. coli, Streptococcus spp;) relative to similar indicators in the control group (who had not recovered from the disease and were not vaccinated). In vaccinated and recovering individuals compared with the control group, the changes are unreliable.
Conclusion: Transmission of COVID-19 in individuals vaccinated with the Gam-COVID-Vac vaccine does not lead to changes in the nasal microbiota. Significant changes in the microbiota with an increase in the number of opportunistic microorganisms were found in unvaccinated individuals who underwent COVID-19.
Supporting agencies: The authors declare that there is no external funding for the exploration and analysis work.
About the Authors
V. A. Romanov
Yaroslavl State Medical University
Russian Federation
Russian Federation
Vitaliy A. Romanov - Dr. Sci. (Med.), Professor, Head of Department.
Yaroslavl
I. V. Dukhanina
Yaroslavl State Medical University
Russian Federation
Russian Federation
Inna V. Dukhanina - Cand. Sci. (Pharm.), Associate Professor of Department.
Yaroslavl
A. V. Afanas'ev
Yaroslavl State Medical University
Russian Federation
Russian Federation
Aleksandr V. Afanas'ev - resident in the specialty “Clinical laboratory diagnostics”.
Yaroslavl
M. Yu. Gul'neva
Yaroslavl State Medical University
Russian Federation
Russian Federation
Marina Yu. Gul'neva - Dr. Sci. (Med.), Associate Professor, Associate Professor of Department
Yaroslavl
N. V. Semechkin
Yaroslavl State Medical University
Russian Federation
Russian Federation
Nikolay V. Semechkin - Cand. Sci. (Med.), Senior Lecturer of Department.
Yaroslavl
References
1. Tsay Monmo, Chen' Yuy, Chen' Tszyobin, Fan Tsyan, Khan' Ve Yli, Khu Shaokhua, Li Tszyan'pin, Li Tong, Lu Syaoyan, Tsyuy Tintin, Shen' Iikhong, Shen Tszifan, Van Khuafen, Vey Gotsin, Syuy Kaytszin', Chzhao Syuekhun, Chzhun Zifen, Chzhou Tszyan'in. Handbook for Prevention and Treatment of COVID-19. Hangzhou: First Clinical Hospital. Zhejiang University Faculty of Medicine; 2020. 68 p. (In Russ.).
2. Nardelli C., Gentile I., Setaro M., Domenico C., Pinchera B., Riccardo Buonomo A., Zappulo E., Scotto R., Luca Scaglione G., Castaldo G.and Capoluongo E. Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum? // Front Cell Infect Microbiol. 2021; 11. doi: 10.3389/fcimb.2021.625581.
3. Gulneva M. Yu., Dukhanina I. V., Malafeeva E. V. Microbiome of the body in case of a coronavirus infection. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular therapy and prevention. 2022; 21 (S2): 39–40 (In Russ.).
4. Bassis С., Tang A., Young V. B., Pynnonen M. A. The nasal cavity microbiota of healthy adults. Microbiome. 2014; 2: 2–27. doi: 10.1186/2049-2618-2-27.
5. Man V. H., de Steenhuysen P., Bogart D. Microbiota of the respiratory tract: the key to respiratory health. Nat. Rev. Microbiol. 2017; 15 (5): 259–270.
6. Logunov D. Y., Dolzhikova I. V., Zubkova O. V., Tukhvatullin A. I., Shcheblyakov D. V., Dzharullaeva A. S., Grousova D. M., Erokhova A. S., Kovyrshina A. V., Botikov A. G., Izhaeva F. M., Popova O., Ozharovskaya T. A., Esmagambetov I. B., Favorskaya I. A., Zrelkin D. I., Voronina D. V., Shcherbinin D. N., Semikhin A. S., Simakova Y. V., Tokarskaya E. A., Lubenets N. L., Egorova D. A., Shmarov M. M., Nikitenko N. A., Morozova L. F., Smolyarchuk E. A., Kryukov E. V., Babira V. F., Borisevich S. V., Naroditsky B. S., Gintsburg A. L. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet. 2020; 396 (10255): 887–897.
7. Vaccines and vaccination: national guidance. Brief edition. Ed. V. V. Zverev, R. M. Haitov, Moscow : GEOTAR-Media; 2014. 640 p. (In Russ.)
8. Lvov D. K. Guide to Virology. Viruses and viral infections of humans and animals. Moscow : MIA; 2013. 1200 p. (In Russ.).
9. SITC Statement on SARS-CoV-2 Vaccination and Cancer Immunotherapy. URL: https://www.sit-cancer.org/aboutsitc/press-releases/2020/sitc-statement-sars-cov-2-vaccination-cerim-munotherapy
10. Tian Y., Rong L., NianW. etal. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol. Ther. 2020; 51 (9): 843–851.
11. Labinskaya A. S., Guide to Medical Microbiology. Opportunistic infections: causative agents and etiological diagnosis. Ed. Kostyukov N. N. Book 3, Volume 1. Moscow: Binom; 2013. 752. (In Russ.).
Review
For citations:
Romanov V.A., Dukhanina I.V., Afanas'ev A.V., Gul'neva M.Yu., Semechkin N.V. Nasal cavity microbiota features among people who have had COVID-19. Astrakhan medical journal. 2023;18(4):97-102. (In Russ.) https://doi.org/10.17021/1992-6499-2023-4-97-102
Views:
286
Email this article 